Oragenics (NYSEMKT:OGEN) just reported results for the second quarter of 2024. Oragenics reported earnings per share of -51 cents. The company did not report any revenue for the quarter.

Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse ...

By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Developing Vaccine Against SARS-CoV-2 In May 2020, Oragenics, Inc. (NYSE:OGEN) announced the acquisition of Noachis ...